Anderson, Kenneth C.

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell

Ubiquitin and proteasome pathwaysMultiple Myeloma Research and Treatments

Cited by 589

Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer

Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 569

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 523

Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

Barlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 495

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 487

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene

Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 478

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research

Cited by 475

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood

Endoplasmic Reticulum Stress and DiseaseMultiple Myeloma Research and Treatments

Cited by 432

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., et al. (2020) · Blood Advances

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 431

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

Carrasco, D. R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D. E., Zheng, M., Mani, M., Henderson, J., Pinkus, G. S., et al. (2007) · Cancer Cell

Multiple Myeloma Research and TreatmentsEndoplasmic Reticulum Stress and Disease

Cited by 414

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 386

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 381

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., et al. (2009) · Blood

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 363

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., et al. (2015) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 309

Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond

Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 305

Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers

Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control

Multiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways

Cited by 292

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Maura, F., Bolli, N., Angelopoulos, N., Dawson, K. J., Leongamornlert, D., Martincorena, I., Mitchell, T. J., Fullam, A., Gonzalez, S., Szalat, R., et al. (2019) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 278

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 271

Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group

Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 258

Genomic patterns of progression in smoldering multiple myeloma

Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 222

RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 219

Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gullà, A., Rossi, M., Neri, A., Giordano, A., Munshi, N. C., et al. (2013) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 219

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 212

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., et al. (2023) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 209